BI drug shown to prevent flares in psoriasis

Country

Germany

An antibody drug developed by Boehringer Ingelheim GmbH to prevent flares in generalised pustular psoriasis (GPP), a rare skin disease, has met its primary and key secondary endpoints in a Phase 2b trial of patients with the disease. Spesolimab (Spevigo) has already been approved for the treatment of the disease.